American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology
LE Schnipper, TJ Smith, D Raghavan… - Journal of Clinical …, 2012 - ascopubs.org
Advancements in the prevention, diagnosis, and treatment of cancer have contributed to
improved survival, better quality of life, and declining death rates in the United States. With …
improved survival, better quality of life, and declining death rates in the United States. With …
Health-related quality of life in non–small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials
L Claassens, J Van Meerbeeck, C Coens… - Journal of Clinical …, 2011 - ascopubs.org
Purpose This study is an update of a systematic review of health-related quality-of-life
(HRQOL) methodology reporting in non–small-cell lung cancer (NSCLC) randomized …
(HRQOL) methodology reporting in non–small-cell lung cancer (NSCLC) randomized …
[HTML][HTML] CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and …
E Felip, A Ardizzoni, T Ciuleanu, M Cobo… - European Journal of …, 2020 - Elsevier
Abstract Background CheckMate 171 (NCT02409368) is an open-label, multicentre, phase
2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer …
2 trial of nivolumab in previously treated advanced squamous non-small cell lung cancer …
New treatment options in advanced squamous cell lung cancer
PK Paik, RN Pillai, CS Lathan, SA Velasco… - American Society of …, 2019 - ascopubs.org
The past few years have witnessed a rapid shift in the treatments for patients with squamous
cell lung cancers (SQCLCs) after the US Food and Drug Administration approval of a …
cell lung cancers (SQCLCs) after the US Food and Drug Administration approval of a …
Use of the lung cancer–specific Quality of Life Questionnaire EORTC QLQ‐LC13 in clinical trials: A systematic review of the literature 20 years after its development
M Koller, S Warncke, MJ Hjermstad, J Arraras… - Cancer, 2015 - Wiley Online Library
The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire‐Lung Cancer 13 (QLQ‐LC13) covers 13 typical symptoms of lung cancer …
Questionnaire‐Lung Cancer 13 (QLQ‐LC13) covers 13 typical symptoms of lung cancer …
[图书][B] Randomised clinical trials: design, practice and reporting
Randomised Clinical Trials: Design, Practice and Reporting provides a detailed overview of
the methodology for conducting clinical trials, including developing protocols, data capture …
the methodology for conducting clinical trials, including developing protocols, data capture …
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung …
C Manegold, J Vansteenkiste, F Cardenal… - Investigational new …, 2013 - Springer
Introduction This multicenter, open-label, phase II study was carried out to compare the
efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface …
efficacy and safety of cilengitide (EMD 121974), a selective inhibitor of the cell-surface …
Medical treatment of advanced non-small cell lung cancer in elderly patients: a review of the role of chemotherapy and targeted agents
G Meoni, FL Cecere, E Lucherini… - Journal of geriatric …, 2013 - Elsevier
Lung cancer is the leading cause of cancer related mortality worldwide. Non-small cell lung
cancer (NSCLC) accounts for 85% of all cases. Half of the patients at diagnosis of NSCLC …
cancer (NSCLC) accounts for 85% of all cases. Half of the patients at diagnosis of NSCLC …
Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy
BACKGROUND: Performance status (PS) is a commonly used factor in determining the
appropriateness for chemotherapy of patients with non-small cell lung cancer (NSCLC). The …
appropriateness for chemotherapy of patients with non-small cell lung cancer (NSCLC). The …
Does very poor performance status systematically preclude single agent anti-PD-1 immunotherapy? A multicenter study of 35 consecutive patients
V Gounant, M Duruisseaux, G Soussi, S Van Hulst… - Cancers, 2021 - mdpi.com
Simple Summary Immunotherapies prolong survival of metastatic non-small-cell lung cancer
patients. However, their efficacy in patients with very poor general condition is unknown …
patients. However, their efficacy in patients with very poor general condition is unknown …